The Medical Xchange

  • Edit profile
  • Logout
Login    Register

Expert Review

NEUROLOGY 2020

Relapsing-Remitting Multiple Sclerosis: Oral First-line Immunomodulators

Liesly Lee, MD
Associate Professor of Medicine (Neurology)
Sunnybrook Health Sciences Centre
University of Toronto
Toronto, Ontario

Oral immunomodulators are an option in the first-line treatment of relapsing-remitting multiple sclerosis (RRMS) in patients unable or unwilling to tolerate the injectable beta interferons or glatiramer acetate (GA). Management of early RRMS agents can be individualized with these first-line options or when de-escalation is being considered. For most patients, an oral immunomodulator provides a reasonable, effective, safe, and appropriate option.

Show review

Disclaimer

The information and opinions expressed herein are those of the participants and do not necessarily reflect those of Xfacto Communications Inc. or the sponsor. The distribution of this meeting report was made possible through industry support under written agreement that ensures editorial independence. The content is for educational purposes and should not be taken as an endorsement of any products, uses or doses. Physicians should consult the appropriate monograph before prescribing any drugs. Distribution, reproduction, alteration of this program is strictly prohibited without written consent of Xfacto Communications Inc. Copyright 2021. All rights reserved. The Medical XchangeTM

This web site is solely for healthcare professionals

Yes, I am a healthcare professional No, I am not a healthcare professional
×
New user?
×
Sign up for the Medical Xchange Here you'll find expert commentary from the most recent medical meetings around the world, as well as features and interviews with top healthcare professionals.
First name* Last name*
Title Gender*
Email* Confirm Email*
Password* Password must have at least 8 characters with at least one Capital letter, one lower case letter and one number or special character Confirm Password*
Profession* Speciality*
Country* Province*